AbbVie has announced that an Irish committee of rheumatology experts is coming together as part of a global initiative seeking solutions to the challenges
Three studies provide more data on risk for major adverse cardiovascular events with JAK inhibitors vs TNF inhibitors, as well as their efficacy in patients with different levels of risk.
Patients with rheumatoid arthritis (RA) are at higher risk for cardiovascular disease than the general population. Systemic inflammation mediates some of this increased risk, therefore it seems logical that treatment with disease-modifying antirheumatic drugs (DMARDs) may be beneficial. A number of abstracts presented at the 2023 annual congress of EULAR – the European Alliance of Associations for Rheumatology – looked at cardiovascular data in RA.
The increased cardiovascular risks in RA include acute coronary syndromes (ACS). The extent to which DMARD-induced remission could reduce the risk of ACS in RA versus rates in the general population – and whether there are DMARD-specific beneficial effects on ACS risk – remain unknown.